← Back to Search

Home-Based Exercise for Chronic Kidney Disease

N/A
Waitlist Available
Led By Elizabeth C Lorenz, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if home-based exercise can improve physical function in frail or pre-frail kidney transplant candidates. Participants will use simple equipment at home to follow a personalized exercise plan. The goal is to enhance their strength, balance, and overall health.

Who is the study for?
This trial is for adults over 18 with any stage of chronic kidney disease who are frail or pre-frail, as measured by specific criteria. They must be able to consent to research and pass a submaximal exercise test if not approved for kidney transplantation. Those with severe heart, lung conditions, or needing multiple organ transplants cannot join.
What is being tested?
The study tests an 8-week home-based exercise program's effectiveness in improving physical function, frailty parameters, SPPB scores (a measure of balance and mobility), quality of life, activity levels, and reducing hospitalizations among kidney transplant candidates.
What are the potential side effects?
While the trial does not list specific side effects due to its nature focusing on exercise intervention rather than medication, participants may experience typical exercise-related discomforts such as muscle soreness or fatigue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Short Physical Performance Battery score
Secondary study objectives
Change in exhaustion
Change in gait speed
Change in grip strength
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Participants will be asked to complete an 8-week home-based exercise intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Chronic Kidney Disease (CKD) include lifestyle modifications like home-based exercise, which aims to improve physical function and quality of life. Exercise helps by enhancing cardiovascular health, reducing inflammation, and improving muscle strength, which are crucial for CKD patients who often suffer from decreased physical function and frailty. Additionally, controlling blood pressure through medications and lifestyle changes is essential to slow the progression of CKD and prevent complications. These treatments matter because they address both the symptoms and underlying causes of CKD, thereby improving patient outcomes and quality of life.
Uremic Sarcopenia: Clinical Evidence and Basic Experimental Approach.

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
1,022 Previous Clinical Trials
6,029,400 Total Patients Enrolled
Mayo ClinicOTHER
3,326 Previous Clinical Trials
3,059,462 Total Patients Enrolled
Elizabeth C Lorenz, MDPrincipal InvestigatorBaylor College of Medicine

Media Library

8 week home-based exercise program Clinical Trial Eligibility Overview. Trial Name: NCT04745169 — N/A
Chronic Kidney Disease Research Study Groups: Intervention
Chronic Kidney Disease Clinical Trial 2023: 8 week home-based exercise program Highlights & Side Effects. Trial Name: NCT04745169 — N/A
8 week home-based exercise program 2023 Treatment Timeline for Medical Study. Trial Name: NCT04745169 — N/A
~3 spots leftby Jun 2025